Sanofi

Sanofi Liabilities

The The Liabilities of Sanofi (SAN.PA) as of Nov 10, 2026 is 55.10 B EUR. In the previous year, The Liabilities was 54.94 B EUR — a change of 0.28% (higher).

Liabilities

55.10 BEUR

YoY

0.28%

Last updated:

In 2025, Sanofi's total liabilities amounted to 55.10 B EUR, a 0.28% difference from the 54.94 B EUR total liabilities in the previous year.

The Sanofi Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
52.37 B EUR
Jan 1, 2019
53.63 B EUR
Jan 1, 2020
51.16 B EUR
Jan 1, 2021
51.21 B EUR
Jan 1, 2022
51.57 B EUR
Jan 1, 2023
52.11 B EUR
Jan 1, 2024
54.94 B EUR
Jan 1, 2025
55.10 B EUR
The Sanofi Liabilities history
YEARLiabilitiesYoY
55.10 BEUR+0.28%
54.94 BEUR+5.43%
52.11 BEUR+1.05%
51.57 BEUR+0.70%
51.21 BEUR+0.10%
51.16 BEUR-4.60%
53.63 BEUR+2.40%
52.37 BEUR+25.98%
41.57 BEUR-11.45%
46.95 BEUR+6.43%
44.11 BEUR+7.26%
41.12 BEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Sanofi's Liabilities

Sanofi's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sanofi's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Sanofi's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Sanofi's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Sanofi’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Sanofi stock

The Liabilities of Sanofi is 55.10 B EUR in 2025.

The Liabilities of Sanofi changed from 54.94 B EUR to 55.10 B EUR, representing a 0.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Sanofi since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Sanofi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Sanofi

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Sanofi